Clinical experience with levosimendan in the emergency department of a tertiary care hospital;Experiencia clínica con levosimendán en un servicio de urgencias de un hospital de tercer nivel

Revista Espanola de Cardiologia

Volumn 60, Issue 8, 2007, Pages 878-882

  Llorens Soriano, Pere ^a   Carbajosa Dalmau, José ^a   Fernández Cañadas, José ^a   Murcia Zaragoza, José ^a   Climent Payá, Vicente ^a   Laghzaoui, Fadoua ^a   Diéguez Zaragoza, Santiago ^a   Carrasco Moreno, Rafael ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

Author keywords

Acute heart failure; Hospital emergency department; Levosimendan

Indexed keywords

LEVOSIMENDAN; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; AGED; ALLOPATHY; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; EMERGENCY WARD; FEMALE; HUMAN; INTENSIVE CARE UNIT; ISCHEMIC HEART DISEASE; MALE; TERTIARY HEALTH CARE; TREATMENT RESPONSE; ACUTE DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; EMERGENCY HEALTH SERVICE; EMERGENCY TREATMENT; PROSPECTIVE STUDY;

ACUTE DISEASE; AGED; CARDIOTONIC AGENTS; EMERGENCY SERVICE, HOSPITAL; EMERGENCY TREATMENT; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; MALE; PROSPECTIVE STUDIES; PYRIDAZINES;

EID: 34548039065     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1157/13109003     Document Type: Article

References (13)

1. Rodríguez-Artalejo J, Banegas Banegas JR, Guallar-Castillón P. Epidemiología de la insuficiencia cardiaca. Rev Esp Cardiol. 2004;57:163-70.
2. Nieminen MS, Bohm M, Cowie MR, Drexler H, Filippatos GS, Jondeau G, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J. 2005;26:384-416.
3. Thackray S, Easthaugh J, Freemantle N, Cleland JGF. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in the patients with heart failure. Eur J Heart Failure. 2002;4:515-29.
4. Parissis JT, Filippatos G, Farmakis D, Adamopoules S, Paraskevaidis I, Kremastinos D. Levosimendan for the treatment of acute heart failure sindromes. Expert Opi Pharmacother. 2005;6:2741-51.
5. Delgado JF. Levosimendán en la insuficiencia cardiaca aguda: pasado, presente y futuro. Rev Esp Cardiol. 2006;59:309-12.
6. Álvarez J, Bouzada M, Fernández AL, Caruezo V, Taboada M, Rodríguez J, et al. Comparación de los efectos hemodinámicos del levosimendán con la dobutamina en pacientes con bajo gasto después de la cirugía. Rev Esp Cardiol. 2006;59:338-45.
7. Follath F, Cleland JG, Just H, Papp JG, Schols H, Peuhjurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output Herat failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360:196-202.
8. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infaction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23:1422-32.
9. Bermejo J, Segovia J, Alfonso F. Resúmenes de los ensayos clínicos presentados en las Sesiones Científicas de la American Heart Association 2005 (Dallas, Texas, Estados Unidos, 13-16 noviembre 2005). Rev Esp Cardiol. 2006;59:143-53.
10. Cleland JGF, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Herat Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006;8:105-10.
11. Vilas-Boas F, Follath F. Current insights into the modern treatment of descompensated heart failure. Arq Bras Cardiol. 2006; 87:329-37
12. Roig E, Pérez-Villa F, Cuppoletti A, Castillo M, Hernández N, Morales M, et al. Programa de atención especializada en la insuficiencia cardiaca terminal. Experiencia piloto de una unidad de insuficiencia cardiaca. Rev Esp Cardiol. 2006;59:109-16.
13. Maclean AS, Huang SJ, Nalos M, Ting I. Duration of the beneficial effects of levosimendan in the descompensated heart failure as measured by echocardiografic indices and B-typed natriuretic peptide. J Cardiovasc Pharmacol. 2005;46:830-5.